key: cord-0732153-5efzormt
authors: Li, Gerui; Li, Hang; Lu, Jinping
title: No adequate evidence indicating hypertension as an independent risk factor for COVID-19 severity
date: 2020-04-23
journal: Clin Res Cardiol
DOI: 10.1007/s00392-020-01653-6
sha: faf5b1c8289fadaf111f96c18332dc20115e76fe
doc_id: 732153
cord_uid: 5efzormt

nan

. Bivariate Cox regression analysis showed that comorbid hypertension was significantly associated with higher incidence of ARDS (HR 1.82 (1.13-2.95), p = 0.005). However, this study did not adjust potential confounding factors, making the real magnitude of the independent association unknown. Therefore, the results from aforementioned studies need to be interpreted cautiously due to the potential bias and limited power. In brief, currently there is no direct evidence indicating comorbid hypertension as an independent risk factor for the severity of COVID-19. Further studies with an appropriate design and adequate power are required to robustly investigate this relationship.

It is suggested by Fang and colleagues that patients with hypertension who are often treated with RAS inhibitors may have an increased risk for COVID-19 infection [4] , since treatment of RAS inhibitors was reported to increase the expression of ACE2, through which SARS-CoV-2 bind to the target cells [5] . On the other hand, previous study demonstrated that ACE2 expression is suppressed following SARS infection, inducing excessively activation of RAS and aggravation of pneumonia [6] . Thus, whether RAS inhibitors increase or decrease the risk for SARS-CoV-2 infection and disease progression has been a recent topic of intense debate. Fang et al. proposed that patients with COVID-19 should be monitored for ACEIs and ARBs, and anti-hypertensive calcium channel blockers could be a suitable alternative treatment [4] . Nevertheless, based on current evidences, we do not suggest arbitrary withdrawl or alteration of usual anti-hypertensive treatment, as complications induced by poorly controlled blood pressure might cause exacerbation of COVID-19 and even death. Indeed, the Council on Hypertension of European Society of Cardiology (ESC) also recommended that treatment with usual anti-hypertensive therapy should be continued, because there is no evidence suggesting the discontinuation of treatment with RAS inhibitors because of the COVID-19 infection [7] .

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

News/posit ion-state ment-of-the-esc-counc il-on-hyper tensi on-on-ace-inhib itors -and-ang

Acknowledgements None.